Anti-streptokinase antibodies and streptokinase resistance in an Aboriginal population in northern Australia

Australian and New Zealand Journal of Medicine

Volumn 26, Issue 1, 1996, Pages 49-53

  Urdahl, K B ^a   Mathews, J D ^b   Currie, B ^b,c  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b MENZIES SCHOOL OF HEALTH RESEARCH   (Australia)

^c ROYAL DARWIN HOSPITAL   (Australia)

Author keywords

Aboriginal health; Myocardial infarction; Streptokinase resistance; Thrombolysis

Indexed keywords

IMMUNOGLOBULIN G; STREPTOKINASE; STREPTOKINASE ANTIBODY; UNCLASSIFIED DRUG;

ABORIGINE; ACUTE HEART INFARCTION; ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ARTICLE; AUSTRALIA; BACTERIAL INFECTION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; ETHNIC DIFFERENCE; HUMAN; STREPTOCOCCUS;

EID: 0029980313     PISSN: 00048291     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1445-5994.1996.tb02906.x     Document Type: Article

References (23)

1. Plant AJ, Condon JR, Durling G. Northern Territory Health Outcomes, Morbidity and Mortality 1979-1991. Northern Territory Department of Health and Community Services, Darwin 1995; 116.
2. Van Buynder PG, Gaggin JA, Martin D, Pugsley D, Mathews JD. Streptococcal infections and renal disease markers in Australian Aboriginal children. Med J Aust 1992; 156: 537-40.
3. Currie, B. Medicine in tropical Australia. Med J Aust 1993; 158: 609-15.
4. McGrath K, Patterson R. Immunology of streptokinase in human subjects. Clin Exp Immunol 1985; 62: 421-6.
5. Youkeles LH, Soliman MY, Rosentreich DL. Use of streptokinase as a recall antigen for lymphocyte proliferation testing in vitro. J Allergy Clin Immunol 1991; 88: 166-71.
6. Gemmill JD, Hogg KJ, Dunn FG, Rae AP, Hillis WS. Predosing antibody levels and efficacy of thrombolytic drugs containing streptokinase. Br Heart J 1994; 72: 222-5.
7. Fears R, Hearn J, Standring R, Anderson JL, Marder VJ. Lack of influence of pretreatment antistreptokinase antibody on efficacy in a multicenter patency comparison of intravenous streptokinase and anistreplase in acute myocardial infarction. Am Heart J 1992; 124: 305-14.
8. Jalihal S, Morris G. Antistreptokinase titres after intravenous streptokinase. Lancet 1990; 335: 184-5.
9. Lynch M, Littler WA, Pentecost BL, Stockley RA. Immunoglobulin response to intravenous streptokinase in acute myocardial infarction. Br Heart J 1991; 66: 139-42.
10. Elliot JM, Cross DB, Cederholm-Williams SA, White HD. Neutralizing antibodies to streptokinase four years after intravenous thrombolytic therapy. Am J Cardiol 1993; 71: 640-5.
11. Lee HS, Cross S, Davidson R, Reid T, Jennings K. Raised levels of antistreptokinase antibody and neutralization titres from 4 days to 54 months after administration of streptokinase or anistreplase. Eur Heart J 1993; 14: 84-9.
12. Cross DB. Should streptokinase be readministered? Insights from recent studies of antistreptokinase antibodies. Med J Aust 1994; 161: 100-1.
13. Lew AS, Cercek B, Hod H, Shah PK, Gam W. Clinical failure of streptokinase due to unsuspected high titer of anti-streptokinase antibody. J Am Coll Cardiol 1984; 4: 183-5.
14. Brugemann J, van der Meer J, Born VJJ, van der Schaaf W, de Graeff PA, Lie KI. Anti-streptokinase antibodies inhibit fibrinolytic effects of anistreplase in acute myocardial infarction. Am J Cardiol 1993; 72: 462-4.
15. White HD, Cross DB, Williams BF, Morris RM. Safety and efficacy of repeat thrombolytic treatment after acute myocardial infarction. Br Heart J 1990; 64: 177-81.
16. Lee HS, Yule S, McKenzie A, et al. Hypersensitivity reactions to streptokinase in patients with high pre-treatment antistreptokinase antibody and neutralisation titres. Eur Heart J 1993; 14: 1640-3.
17. Fleiss JL. Statistical methods for rates and proportions. 2nd edition. New York: John Wiley, 1981.
18. Deutsch E, Fisher M. Die Wirkung intravenous applizierter streptokinase af fibrinolyse und blutgerinnumg. Thromb Haemost 1960; 4: 482-506.
19. McGrath KG, Zeffren B, Alexander J, Kaplan J, Patterson R. Allergic reactions to streptokinase consistent with anaphylactic or antigen complex mediated damage. J Allergy Clin Immunol 1984; 76: 453-7.
20. Siebert WJ, Ayres RW, Bulling MT, Thomas CM, Minson RB, Aylward PE. Streptokinase morbidity - more common than previously recognized. Aust NZ J Med 1992; 22: 129-33.
21. Taylor BV, Mastaglia FL, Stell R. Guillain-Barre syndrome complicating treatment with streptokinase. Med J Aust 1995; 162: 214-5.
22. Massel D, Turpie AGG, Cairns JA, Ofusa FA, Buchanan MR. Previous streptokinase (SK) therapy inhibits subsequent SK thombolysis [Abstr.]. Circulation 1991; 84(Suppl II): 11-467.
23. Shaila G, Chandreshekhar YS, Kumar N, Ganguly NK, Anand IS. Antistreptokinase antibodies before and after streptokinase therapy in patients with acute myocardial infarction from areas endemic for streptococcal infection and influence on reperfusion rates. Am J Cardiol 1994; 74: 187-9.